Now showing items 65-84 of 84

      Reporting of Drug Benefit in FDA-Approved Prescription Drug Labeling. [1]
      Restoring biomedical literature with RIAT [1]
      Restoring invisible and abandoned trials: a call for people to publish the findings [1]
      Rethinking credible evidence synthesis [1]
      Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reports [1]
      Speeding new antibiotics to market: a fake fix? [1]
      Statins for primary prevention: what is the regulator’s role? [1]
      Transparency too little, too late? Why and how Health Canada should make clinical data and regulatory decision-making open to scrutiny in the face of COVID-19 [1]
      Trends in recorded influenza mortality: United States, 1900-2004 [1]
      The unofficial vaccine educators: are CDC funded non-profits sufficiently independent? [1]
      Update: New England Journal of Medicine publishes correction to 2012 CHEST trial of hydroxyethyl starch versus colloids [1]
      US government website for collecting adverse events after vaccination is inaccessible to most users [1]
      US incentive scheme for neglected diseases: a good idea gone wrong? [1]
      The use of clinical study reports to enhance the quality of systematic reviews: a survey of systematic review authors [1]
      Visualising childhood vaccination schedules across G8 countries [1]
      When to include clinical study reports and regulatory documents in systematic reviews [1]
      WHO’s malaria vaccine study represents a “serious breach of international ethical standards” [1]
      The wider role of regulatory scientists [1]
      Will covid-19 vaccines save lives? Current trials aren't designed to tell us [1]
      YODA and truth seeking in medicine [1]